547 related articles for article (PubMed ID: 30168880)
1. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
2. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
4. Apremilast in psoriasis - a prospective real-world study.
Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
8. Drug survival of apremilast in a real-world setting.
Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
[TBL] [Abstract][Full Text] [Related]
10. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
12. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
14. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
[TBL] [Abstract][Full Text] [Related]
17. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience With Apremilast in Treating Psoriasis.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
[No Abstract] [Full Text] [Related]
20. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
